Tourmaline Bio is well-funded, with cash runway into 2H 2027, minimizing near-term dilution risk for investors. Click here to ...

Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data demonstrate the potential for dosing two to ...

Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin approved for add-on severe asthma treatment in 2021 ...

Mepolizumab added to triple therapy improves exacerbation outcomes in moderate to severe COPD and is effective to 2 years of ...

The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate ...

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD ...

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine mesylate) injection ...

Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

Brekiya consists of dihydroergotamine mesylate, an ergotamine derivative, in a single-dose autoinjector for subcutaneous administration.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Janssen, the pharmaceutical arm of Johnson & Johnson and a leader in healthcare, has announced the launch of Tecvayli in the ...